Table 1 |
||||||
|
Recognition of U1-70K (70K) and its apoptotic cleavage product (70Kapop) by patients with different autoimmune disorders |
||||||
|
No. (%) of patients with disorder |
||||||
|
|
||||||
|
Patient group (disease) |
No. of patients |
70Kapop |
70Kapop > 70K |
70Kapop = 70K |
70K > 70Kapop |
70K |
|
|
||||||
|
MCTD |
53 |
15 (28) |
14 (26) |
7 (13) |
1 (2) |
2 (4) |
|
SLE |
48 |
0 |
1 (2) |
1 (2) |
0 |
1 (2) |
|
Non-SLEa |
61 |
0 |
0 |
0 |
0 |
2 (3) |
|
|
||||||
|
aThe control group of non-systemic lupus erythematosus (non-SLE) patients consists of patients suffering from polymyositis/dermatomyositis (n = 26), primary Sjögren's syndrome (n = 18), systemic sclerosis (n = 10), rheumatoid arthritis (n = 3), Raynaud's phenomenon (n = 3) and undefined connective tissue disease (n = 1). MCTD, mixed connective tissue disease. |
||||||
|
Hof et al. Arthritis Res Ther 2005 7:R302 doi:10.1186/ar1490 |
||||||
